🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Excessive Daytime Sleepiness

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue NCT06170970Phase 21 site📍 Baltimore Johns Hopkins University · Tests: Solriamfetol, Placebo Digital Sleep Program for College Students with Insomnia NCT06853106NA1 site📍 Taipei Taipei Medical University · Tests: Waitlist control group, digital-based multimodal sleep management program A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence NCT07598708Phase 2, Phase 323 sites📍 Birmingham📍 Colorado Springs📍 Brandon Centessa Pharmaceuticals (UK) Limited · Tests: cleminorexton, Placebo A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) NCT07540897Phase 320 sites📍 Brandon📍 Miami📍 Winter Park Alkermes, Inc. · Tests: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo A Study Assessing Adult Patients Referred to an NHS Sleep Service With Suspected Obstructive Sleep Apnoea. This Study Aims to Compare the Sunrise Wearable Diagnostic Device Performance and Potential Inclusion in a NHS Diagnostic Pathway With Oximetry and WatchPAT Which Are Currently Used. NCT07269483NA1 site📍 Bristol Virginia Hawkins · Tests: WatchPAT 300, Oximetry, Sunrise A Study of Pitolisant in Patients With Prader-Willi Syndrome NCT06366464Phase 357 sites📍 Los Angeles📍 Sacramento📍 San Diego Harmony Biosciences Management, Inc. · Tests: Pitolisant tablet, Placebo tablet A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age NCT07082829Phase 13 sites📍 Lincoln📍 Eatontown📍 New York Centessa Pharmaceuticals (UK) Limited · Tests: ORX142 Tablets, Placebo Tablets Promoting Teenage Sleep for Improved Mental Health and School Performance NCT06306092NA1 site📍 Kristianstad Kristianstad University · Tests: Sleep on Schedule, Technology restriction A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) NCT07500090Phase 342 sites📍 Birmingham📍 Peoria📍 Redwood City Harmony Biosciences Management, Inc. · Tests: HBS-301 tablet, Placebo Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal NCT06872593NA1 site📍 Zurich Stefan Lakämper · Tests: CPAP-withdrawal, Test Sequence A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia NCT06767683Phase 2, Phase 350 sites📍 Cullman📍 Phoenix📍 Little Rock Alkermes, Inc. · Tests: ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg Sleep and Stroke Rehabilitation Study NCT07579871n/a1 site📍 Lund Malin Eleonora av Kák Gustafsson, MD, PhD A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder NCT07901179Phase 21 site📍 Jacksonville Alkermes, Inc. · Tests: ALKS 7290 Dose, Placebo Morning Bright Light Therapy and Daytime Functioning in University Students NCT07685262NA1 site📍 Hung Hom The Hong Kong Polytechnic University · Tests: Bright light therapy (10,000 lux light box) A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia NCT07096674Phase 224 sites📍 Auburn📍 Santa Ana📍 Miami Centessa Pharmaceuticals (UK) Limited · Tests: ORX750, ORX750, ORX750 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 NCT07455383Phase 344 sites📍 Cullman📍 Phoenix📍 Los Angeles Alkermes, Inc. · Tests: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE) NCT07540364Phase 31 site📍 Columbia Suven Life Sciences Limited · Tests: Samelisant, Placebo Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol NCT07484217Phase 340 sites📍 Tucson📍 Bellflower📍 Chino Axsome Therapeutics, Inc. · Tests: Solriamfetol 150 MG, Placebo SLEEPINESS - a Search for a Biomarker of Excessive Daytime Sleepiness in Severe Obstructive Sleep Apnoea - An Explorative Study NCT06711159n/a1 site📍 Koege Zealand University Hospital · Tests: continuous positive airway pressure A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 NCT07502443Phase 344 sites📍 Cullman📍 Phoenix📍 Los Angeles Alkermes, Inc. · Tests: ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy